Your browser doesn't support javascript.
loading
New International Association for the Study of Lung Cancer (IASLC) Pathology Committee Grading System for the Prognostic Outcome of Advanced Lung Adenocarcinoma.
Weng, Ching-Fu; Huang, Chi-Jung; Huang, Shih-Hung; Wu, Mei-Hsuan; Tseng, Ailun Heather; Sung, Yung-Chuan; Lee, Henry Hsin-Chung; Ling, Thai-Yen.
Afiliación
  • Weng CF; Division of Pulmonary Medicine, Department of Internal Medicine, Hsinchu Cathay General Hospital, Hsinchu 300, Taiwan.
  • Huang CJ; Department and Graduate Institute of Pharmacology, National Taiwan University, Taipei 100, Taiwan.
  • Huang SH; Medical Research Center, Cathay General Hospital, Taipei 106, Taiwan.
  • Wu MH; Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan.
  • Tseng AH; School of Medicine, Fu Jen Catholic University, New Taipei 242, Taiwan.
  • Sung YC; Division of Pathology, Cathay General Hospital, Taipei 106, Taiwan.
  • Lee HH; Teaching and Research Center, Hsinchu Cathay General Hospital, Hsinchu 300, Taiwan.
  • Ling TY; Department of Biomedical Sciences and Engineering, National Central University, Taoyuan 320, Taiwan.
Cancers (Basel) ; 12(11)2020 Nov 18.
Article en En | MEDLINE | ID: mdl-33218158
The impact of the new International Association for the Study of Lung Cancer pathology committee grading system for advanced lung adenocarcinoma (LADC) on survival is unclear, especially in Asian populations. In this study, we reviewed the prognostic outcomes of patients with late-stage disease according to the new grading system. We reviewed 136 LADC cases who underwent a small biopsy from 2007 to 2018. Tumors were classified according to the new grading system for LADC. Baseline characteristics (age, sex, smoking status, body mass index, and driver gene mutations) were analyzed. Kaplan-Meier and Cox regression analyses were used to determine correlations with the new grading system and prognosis. Patients with poorly differentiated adenocarcinoma were significantly correlated with a poor progression-free survival (PFS) (p = 0.013) but not overall survival (OS) (p = 0.154). Subgroup analysis showed that wild-type EGFR patients with poorly differentiated adenocarcinoma treated with chemotherapy had significantly worse PFS (p = 0.011). There was no significant difference in survival among the patients with epidermal growth factor receptor mutations who were treated with tyrosine kinase inhibitors. Patients aged >70 years and those with a BMI ≤ 25 kg/m2 and wild-type patients had significantly worse OS in both univariate (HR = 1.822, p = 0.006; HR = 2.250, p = 0.004; HR = 1.537, p = 0.046, respectively) and multivariate analyses (HR = 1.984, p = 0.002; HR = 2.383, p = 0.002; HR = 1.632, p = 0.028, respectively). Despite therapy, patients with poorly differentiated tumors still fared worse than those with better differentiated tumors. No differences were found among the EGFR mutations treated with TKI. Our findings highlight that the therapeutic regimen should be adjusted for EGFR Wild-type patients with poorly differentiated adenocarcinoma treated with chemotherapy to provide better outcomes.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Taiwán

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Taiwán